In vitro activity of Retapamulin against Staphylococcus aureus resistant to various antimicrobial agents

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4547-4550

  Saravolatz, Louis D ^a   Pawlak, Joan ^a   Saravolatz, Stephanie N ^a   Johnson, Leonard B ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; MINOCYCLINE; PSEUDOMONIC ACID; RETAPAMULIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 84882416867     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00282-13     Document Type: Article

References (11)

1. Champney WS, Rodgers WK. 2007. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:3385-3387.
2. Kosowska-Shick K, Clark C, Credito K, McGhee P, Dewasse B, Bogdanovich T, Appelbaum PC. 2006. Single and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769.
3. Moody MN, Morrison LK, Tyring SK. 2010. Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett. 15:1-4.
4. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Traczewski MM, Brown SD. 2008. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 52:3863-3867.
6. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Pearson RD, Steigbigel RT, Davis HT, Chapman SW. 1980. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708.
8. Isenberg HD (ed). 2004. Clinical microbiology procedures handbook, p 5.1.2. ASM Press, Washington, DC.
9. Tam VH, Schilling AN, Nikolaou M. 2005. Modeling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55:699-706.
10. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. 2010. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J. Antimicrob. Chemother. 65:2329-2335.
11. Candel FG, Morales G, Picazo J. 2011. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates. Rev. Esp. Quimioter. 24:127-130.